MétaCan
Menu
Back to cohort
Record W2774624088 · doi:10.1016/j.bbmt.2017.11.025

Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia

2017· article· en· W2774624088 on OpenAlexaff
Partow Kebriaei, Claudio Anasetti, Mei‐Jie Zhang, Hailin Wang, Ibrahim Aldoss, Marcos de Lima, H. Jean Khoury, Brenda M. Sandmaier, Mary M. Horowitz, Andrew Artz, Nelli Bejanyan, Stefan O. Ciurea, Hillard M. Lazarus, Robert Peter Gale, Mark R. Litzow, Christopher Bredeson, Matthew D. Seftel, Michael A. Pulsipher, Jaap Jan Boelens, Joseph Alvarnas, Richard E. Champlin, Stephen J. Forman, Vinod Pullarkat, Daniel J. Weisdorf, David I. Marks, William J. Hogan, Minoo Battiwalla, Edward A. Copelan, Gerhard Hildebrandt, Sid Ganguly, Navneet S. Majhail, Ann E. Woolfrey, Ian Nivison‐Smith, Mark Hertzberg, Miguel Ángel Díaz, Ann A. Jakubowski, Celalettin Üstün, Agnes S. M. Yong, César O. Freytes, Zachariah DeFilipp, Yoshi Inamoto, Jean‐Yves Cahn, Bipin N. Savani, Jean A. Yared, Ashish Bajel, Ulrike Bacher, Geoffrey L. Uy, David A. Rizzieri, Matthew J. Wieduwilt, Kirk R. Schultz, Michael R. Grunwald, Rammurti T. Kamble, Muna Qayed, Jonathan E. Brammer, Karen K. Ballen, Nandita Khera, Harry C. Schouten, Marc Bierings, Christopher G. Kanakry, William A. Wood, Ayman Saad, Lynn Savoie, Betty K. Hamilton, Mahmoud Aljurf, Ravi Vij, Attaphol Pawarode, Richard F. Olsson, Baldeep Wirk, Amer Beitinjaneh, Sachiko Seo, Jan Černý, Görgün Akpek, Maxim Norkin, Taiga Nishihori, Aleksandr Lazaryan, Mitchell Sabloff

Bibliographic record

VenueBiology of Blood and Marrow Transplantation · 2017
Typearticle
Languageen
FieldMedicine
TopicHematopoietic Stem Cell Transplantation
Canadian institutionsCancerCare ManitobaOttawa Hospital
FundersGamida CellNational Institute of Allergy and Infectious DiseasesOffice of Naval ResearchJanssen Scientific AffairsHealth Resources and Services AdministrationOtsuka PharmaceuticalAstellas PharmaU.S. Department of Health and Human ServicesMiltenyi BiotecPatient-Centered Outcomes Research InstituteIncyteSeattle GeneticsTelomere DiagnosticsAlexion Pharmaceuticalsbluebird bioJazz PharmaceuticalsSunesisMedacAstraZenecaGenentechChimerixU.S. Department of DefenseMedical College of WisconsinNational Heart, Lung, and Blood InstituteNovartis Pharmaceuticals CorporationTakeda OncologyUniversity of MinnesotaMerckSpectrum PharmaceuticalsRoswell Park Cancer InstituteFred Hutchinson Cancer Research CenterSt. Baldrick's FoundationGenzymeNational Cancer InstituteGilead SciencesLeukemia and Lymphoma SocietyU.S. NavyCelgeneWellPointHealth ResearchNational Marrow Donor ProgramBristol-Myers SquibbAstellas Pharma USOtsuka America PharmaceuticalAmgenBe The Match FoundationMedImmuneSanofiOnyx Pharmaceuticals
KeywordsMedicineBusulfanLymphoblastic LeukemiaTotal body irradiationConditioningInternal medicineLeukemiaOncologyChemotherapyCyclophosphamide

Abstract

fetched live from OpenAlex

Total body irradiation (TBI) has been included in standard conditioning for acute lymphoblastic leukemia (ALL) before hematopoietic cell transplantation (HCT). Non-TBI regimens have incorporated busulfan (Bu) to decrease toxicity. This retrospective study analyzed TBI and Bu on outcomes of ALL patients 18-60 years old, in first or second complete remission (CR), undergoing HLA-compatible sibling, related, or unrelated donor HCT, who reported to the Center for International Blood and Marrow Transplant Research from 2005 to 2014. TBI plus etoposide (25%) or cyclophosphamide (75%) was used in 819 patients, and intravenous Bu plus fludarabine (41%), clofarabine (30%), cyclophosphamide (15%), or melphalan (13%) was used in 299 patients. Bu-containing regimens were analyzed together, since no significant differences for patient outcomes were noted between them. Bu patients were older, with better performance status; took longer to achieve first CR and receive HCT; were treated more recently; and were more likely to receive peripheral blood grafts, antithymocyte globulin, or tyrosine kinase inhibitors. With median follow-up of 3.6 years for Bu and 5.3 years for TBI, adjusted 3-year outcomes showed treatment-related mortality Bu 19% versus TBI 25% (P = .04); relapse Bu 37% versus TBI 28% (P = .007); disease-free survival (DFS) Bu 45% versus TBI 48% (P = .35); and overall survival (OS) Bu 57% versus TBI 53% (P = .35). In multivariate analysis, Bu patients had higher risk of relapse (relative risk, 1.46; 95% confidence interval, 1.15 to 1.85; P = .002) compared with TBI patients. Despite the higher relapse, Bu-containing conditioning led to similar OS and DFS following HCT for ALL.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.008
GPT teacher head0.236
Teacher spread0.228 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations97
Published2017
Admission routes1
Has abstractyes

Explore more

Same venueBiology of Blood and Marrow TransplantationSame topicHematopoietic Stem Cell TransplantationFrench-language works237,207